shutterstock_1010946472_nitpicker-2
nitpicker / Shutterstock.com
1 July 2020Big Pharma

Chiesi blocks Japanese drugmaker’s new brand at EU General Court

Japan-based Nitto Pharmaceutical Industries has been blocked from using its ‘Noster’ brand in the EU, in a win for Italian drugmaker  Chiesi Farmaceutici.

According to  Nitto Pharma’s website, Noster is a new company established in Japan last month, and specialises in gut microbiome drug discovery.

Nitto Pharma filed a trademark application for the brand name at the European Union Intellectual Property Office (EUIPO) as far back as 2016, but was opposed by Chiesi.

Chiesi argued that the name was likely to cause confusion with ‘Foster’, the brand name for Chiesi’s inhaler for treating asthma and chronic obstructive pulmonary disease.

In May 2019, an EUIPO appeals board sided with Chiesi and blocked Nitto from registering the ‘Noster’ trademark, on the basis that it was possible the public could confuse the two brands.

The Japanese firm appealed to the EU General Court, which has now affirmed the EUIPO’s previous decision and ordered Nitto to pay Chiesi’s legal costs.

Nitto had argued that there was a sufficient difference between the letters ‘n’ and ‘f’ to ward off any likelihood of the public confusing the two brands.

It also claimed that the EUIPO had set the bar for a likelihood of confusion too low.

But the General Court rejected those arguments, finding that the EUIPO didn’t have to “prove that there was an absolute certainty” of confusion, but rather only “show that there was a ‘risk’ that consumers may believe that the goods or services in question come from the same undertaking”.

Chiesi is also involved in a separate patent dispute with Israeli generics maker Teva, over the Foster inhaler, or Fostair as it is known in the UK.

Justice Colin Birss of the English High Court last month ruled that Teva had to face infringement claims brought by Chiesi, after the generics manufacturer unsuccessfully tried to have them thrown out.

Did you enjoy reading this story?  Sign up to our free daily newsletters and get stories sent like this straight to your inbox.


More on this story

Biotechnology
8 March 2022   Should the MHLW and CSIMC consider competition in drug pricing, it would be necessary to formulate systems to utilise the expertise of a competition expert, namely the Japan Fair Trade Commission, says Takanori Abe of Abe & Partners.
Europe
3 June 2020   Israeli generic drugmaker Teva Pharmaceuticals must face infringement claims related to an asthma inhaler, an English judge has ruled.
Generics
25 November 2020   The European Commission wants to increase access to generic medicines and crack down on anti-competitive behaviour in the pharmaceutical industry, a new plan has said.

More on this story

Biotechnology
8 March 2022   Should the MHLW and CSIMC consider competition in drug pricing, it would be necessary to formulate systems to utilise the expertise of a competition expert, namely the Japan Fair Trade Commission, says Takanori Abe of Abe & Partners.
Europe
3 June 2020   Israeli generic drugmaker Teva Pharmaceuticals must face infringement claims related to an asthma inhaler, an English judge has ruled.
Generics
25 November 2020   The European Commission wants to increase access to generic medicines and crack down on anti-competitive behaviour in the pharmaceutical industry, a new plan has said.